Indivior (INVVY) Raised to “Hold” at Zacks Investment Research

Zacks Investment Research upgraded shares of Indivior (OTCMKTS:INVVY) from a sell rating to a hold rating in a research note released on Thursday.

According to Zacks, “Indivior PLC operates as a specialty pharmaceutical company. It is engaged in discovering and developing medications and treatment for alcohol addiction, opioid overdose, cocaine intoxication and co-occurring conditions, such as schizophrenia. The Company markets and promotes SUBOXONE (buprenorphine and naloxone) Sublingual Film, SUBOXONE (buprenorphine and naloxone) Sublingual Tablet, and SUBUTEX (buprenorphine) Sublingual Tablet, each buprenorphine-based treatment for opioid. Indivior PLC is based in United States. “

Separately, ValuEngine upgraded Indivior from a hold rating to a buy rating in a report on Wednesday, November 29th.

Indivior (OTCMKTS INVVY) opened at $28.26 on Thursday. Indivior has a twelve month low of $17.50 and a twelve month high of $30.10. The firm has a market capitalization of $4,290.00, a price-to-earnings ratio of 113.06, a PEG ratio of 3.00 and a beta of 0.79.

WARNING: This news story was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The original version of this news story can be read at

Indivior Company Profile

Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence worldwide. The company’s product candidates focus on treating opioid use disorder, alcohol use disorder, overdose rescue, and CNS disorders/schizophrenia.

Get a free copy of the Zacks research report on Indivior (INVVY)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with's FREE daily email newsletter.

Leave a Reply